The efficacy and safety of auranofin in the treatment of juvenile rheumatoid arthritis. A long-term open study. 1988

R Marcolongo, and A Mathieu, and R Pala, and N Giordano, and A Fioravanti, and R Panzarasa
Institute of Rheumatology, University of Siena, Italy.

The safety and efficacy of auranofin in the long-term treatment of children with juvenile rheumatoid arthritis was investigated in an open study of 14 patients. Twelve patients completed at least 12 months of treatment, and 7 patients completed 36 months of treatment. Classic parameters of disease activity showed improvement over baseline values after 6 months of treatment, and laboratory indices remained stable or improved throughout the study. Auranofin was well tolerated; the frequency of adverse effects was lower in these patients than has been previously reported in either adults or children whose arthritis has been treated with injectable gold.

UI MeSH Term Description Entries
D008297 Male Males
D011537 Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief. Itching,Pruritis
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D001171 Arthritis, Juvenile Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent. Arthritis, Juvenile Chronic,Arthritis, Juvenile Idiopathic,Arthritis, Juvenile Rheumatoid,Childhood Arthritis,PCJIA,PJIA Polyarticular Juvenile Idiopathic Arthritis,Polyarticular Juvenile Idiopathic Arthritis,Polyarticular-Course Juvenile Idiopathic Arthritis,Still's Disease, Juvenile-Onset,Enthesitis-Related Arthritis, Juvenile,Juvenile Chronic Arthritis,Juvenile Idiopathic Arthritis,Juvenile Rheumatoid Arthritis,Juvenile-Onset Still Disease,Juvenile-Onset Stills Disease,Oligoarthritis, Juvenile,Polyarthritis, Juvenile, Rheumatoid Factor Negative,Polyarthritis, Juvenile, Rheumatoid Factor Positive,Psoriatic Arthritis, Juvenile,Still Disease, Juvenile-Onset,Systemic Arthritis, Juvenile,Arthritides, Childhood,Arthritis, Childhood,Arthritis, Juvenile Enthesitis-Related,Arthritis, Juvenile Psoriatic,Arthritis, Juvenile Systemic,Childhood Arthritides,Chronic Arthritis, Juvenile,Enthesitis Related Arthritis, Juvenile,Idiopathic Arthritis, Juvenile,Juvenile Arthritis,Juvenile Enthesitis-Related Arthritis,Juvenile Oligoarthritis,Juvenile Onset Still Disease,Juvenile Onset Stills Disease,Juvenile Psoriatic Arthritis,Juvenile Systemic Arthritis,Juvenile-Onset Still's Disease,Rheumatoid Arthritis, Juvenile,Still Disease, Juvenile Onset,Still's Disease, Juvenile Onset,Stills Disease, Juvenile-Onset
D001310 Auranofin An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious. Crisinor,Ridaura,Ridauran,SK&F D 39162,SK&F-39162,SK&F 39162,SK&F39162

Related Publications

R Marcolongo, and A Mathieu, and R Pala, and N Giordano, and A Fioravanti, and R Panzarasa
June 1985, The Journal of rheumatology,
R Marcolongo, and A Mathieu, and R Pala, and N Giordano, and A Fioravanti, and R Panzarasa
June 1984, Clinical rheumatology,
R Marcolongo, and A Mathieu, and R Pala, and N Giordano, and A Fioravanti, and R Panzarasa
January 1983, The Journal of pediatrics,
R Marcolongo, and A Mathieu, and R Pala, and N Giordano, and A Fioravanti, and R Panzarasa
February 2005, Arthritis and rheumatism,
R Marcolongo, and A Mathieu, and R Pala, and N Giordano, and A Fioravanti, and R Panzarasa
June 2006, Arthritis and rheumatism,
R Marcolongo, and A Mathieu, and R Pala, and N Giordano, and A Fioravanti, and R Panzarasa
January 1986, Scandinavian journal of rheumatology. Supplement,
R Marcolongo, and A Mathieu, and R Pala, and N Giordano, and A Fioravanti, and R Panzarasa
August 2002, Minerva medica,
R Marcolongo, and A Mathieu, and R Pala, and N Giordano, and A Fioravanti, and R Panzarasa
April 2010, Annals of the rheumatic diseases,
R Marcolongo, and A Mathieu, and R Pala, and N Giordano, and A Fioravanti, and R Panzarasa
January 1982, The Journal of rheumatology. Supplement,
R Marcolongo, and A Mathieu, and R Pala, and N Giordano, and A Fioravanti, and R Panzarasa
January 1977, Scandinavian journal of rheumatology,
Copied contents to your clipboard!